Ulz covers the Healthcare sector, focusing on stocks such as Silence Therapeutics, Viking Therapeutics, and IO Biotech. According to TipRanks, Ulz has an average return of 2.7% and a 40.66% success ...
Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...
A fortnight off between busy periods for Stoke City as they try to show they are moving in the right direction under another ...
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors ...
Zacks.com on MSN3d
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateKey Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...
So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback